Why Invest in Deos?
First and only gene therapy program in development for LBSL (DARS2 deficiency), an untreatable and likely often misdiagnosed CNS leukodystrophy
LBSL qualifies for orphan drug designation and potential regulatory incentives
DARS2 biology has been studied by our team since 2016. The team has validated testing of the gene therapy in patient cells, two mouse models, and multiple vectors to understand the nuance of delivery and expression
DEOS-101 is advancing rapidly toward clinical trial with strong preclinical safety and efficacy data
A uniquely underserved space with high unmet need and limited competition
Executives and scientists with track records in gene therapy, regulatory science, and biotech growth
Near-term INDs, strong preclinical efficacy, and validated targets
Open to strategic alliances, co-development, and platform licensing
enters IND-enabling studies
with multiple academic partners since 2020
for DEOS-101 in 2027
from leading neuro and biotech firms and institutes
forming in vector development, safety, imaging and biomarker discovery